Oppenheimer analyst, Christopher Marai, anticipates a narrowly positive BioMarin (NASDAQ: BMRN) Kyndrisa panel outcome, and discussion highlighting key differentiation of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE